Compare Boston Scientific Corporation (BSX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ProShares UltraPro Short QQQ ETF — how do they compare? Boston Scientific Corporation trades at $43.48 (market cap $66.37B), while ProShares UltraPro Short QQQ ETF trades at $39.64. Which is the better fit depends on your goals.
| BSX | SQQQ | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.14 | $97.60 |
52-Week Low | $42.63 | $36.31 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SQQQ (ProShares UltraPro Short QQQ ETF) trades at $39.95, up 5.74% ($2.17) in the last session. The ETF shows a neutral technical signal overall with bullish moving averages and neutral oscillators. Recent news highlights SQQQ's role as a tactical hedging tool against Nasdaq 100 declines, though long-term performance erosion due to daily -3x leverage remains a concern. Short interest increased 19.4% in March 2026, reflecting bearish sentiment toward tech.
Outlook: SQQQ is a high-risk, short-term instrument for hedging QQQ exposure, not a long-term investment. Opportunities exist for tactical investors during tech selloffs, but risks include volatility decay, timing challenges, and structural erosion. Investors should understand the leveraged ETF's mechanics and use it cautiously within a diversified strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
